Ishihara Kae, Namura Tomoyo, Murayama Hiroshi, Arai Satoshi, Totani Masayuki, Ikemoto Masaki
Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Rinsho Byori. 2009 Apr;57(4):324-31.
We previously hypothesized that S100A8/A9 binds with several kinds of proinflammatory cytokines, such as TNF-alpha, IL-6 and IL-1beta, to form the S100A8/A9-proinflammatory cytokine complexes in vivo in acute inflammation, leading to subsidence of inflammatory responses. Our goal was to verify the presence of these complexes in liver tissues of rats with lipopolysaccharide (LPS) induced damage. We firstly prepared two kinds of the full-length cDNA encoding amino acid sequences of human S100A8 and S100A9 proteins, and constructed their pCold-I expression vectors. The recombinant S100A8 and S100A9 were successfully expressed in E. coli, and then purified by Ni-agarose columns, respectively. The S100A8/A9 was noncovalently synthesized in 2.0 mol/1 Tris-NaOH solution (pH 12) using the purified S100A8 and S100A9. After purification, this heterodimer (1 mg) was intraperitoneally injected into a rat 1h after injection of LPS. Two kinds of ELISA systems were used to detect the S100A8/A9-inflammatory cytokine complexes in the rat liver tissue. As determined by the ELISA-A and B, the reaction was apparently positive and quantitative. Immunohistochemistry provided such complexes-positive cells in the liver with damage. The S100A8/A9-positive cells almost corresponded to the cytokines-positive ones morphologically, strongly suggested the presence of the S100A8/A9-proinflammatory cytokine complexes. In conclusion, the possibility that these complexes were formed in vivo and accumulated to the immunological cells, such as macrophages and/or activated neutrophils, was indicated. Our effort is currently addressed to isolate the S100A8/A9-proinflammatory cytokine complexes using biochemical techniques, and to comprehensively resolute their clinical significance in the differential diagnosis of inflammatory diseases.
我们之前曾推测,在急性炎症的体内环境中,S100A8/A9与多种促炎细胞因子(如肿瘤坏死因子-α、白细胞介素-6和白细胞介素-1β)结合,形成S100A8/A9-促炎细胞因子复合物,从而导致炎症反应消退。我们的目标是验证这些复合物在脂多糖(LPS)诱导损伤的大鼠肝脏组织中是否存在。我们首先制备了两种编码人S100A8和S100A9蛋白氨基酸序列的全长cDNA,并构建了它们的pCold-I表达载体。重组的S100A8和S100A9在大肠杆菌中成功表达,然后分别通过镍琼脂糖柱进行纯化。使用纯化后的S100A8和S100A9在2.0 mol/1 Tris-NaOH溶液(pH 12)中通过非共价方式合成S100A8/A9。纯化后,将这种异二聚体(1 mg)在注射LPS 1小时后腹腔注射到大鼠体内。使用两种酶联免疫吸附测定(ELISA)系统检测大鼠肝脏组织中的S100A8/A9-炎症细胞因子复合物。通过ELISA-A和ELISA-B测定,反应明显呈阳性且可定量。免疫组织化学显示肝脏中存在这些复合物阳性细胞,且有损伤。S100A8/A9阳性细胞在形态上几乎与细胞因子阳性细胞相对应,强烈提示存在S100A8/A9-促炎细胞因子复合物。总之,表明了这些复合物在体内形成并积累到免疫细胞(如巨噬细胞和/或活化的中性粒细胞)中的可能性。我们目前正致力于使用生化技术分离S100A8/A9-促炎细胞因子复合物,并全面解析它们在炎症性疾病鉴别诊断中的临床意义。